CBIO Company Profile and Key Details

CBIO has shown sold momentum, gaining 27.32% over the past week and 11.48% over the past quarter, though year-to-date performance is up 17.88%. Short-term trend indicators are bullishly aligned (SMA20 20.06%, SMA50 8.73%, SMA200 -10.65%). The stock’s 14-day RSI is 62.01 (firm momentum), while the ATR of 0.97 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -57.52% below its high and over 41.57% above its low. Average 10-day trading volume of 865.31 thousand shares is significantly above the 3-month average of 402.75 thousand, indicating heightened recent market interest.

Crescent Biopharma, Inc. generated EPS of -$21.97 over the past year. Five-year average earnings growth is 15.18%. Wall Street analysts project EPS growth of 58.9% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $25.00. The high target offers 107.22% upside. The low target suggests 48.02% downside. The mean target is $29.00. This offers 71.7% upside. Crescent Biopharma, Inc. earnings surprise history is a mixed track record. The quarter that ended July 30, 2026, missed forecasts by 5.71%. The prior quarter beat by -17.65%. Over the last six quarters, Apple has recorded several small beats. These include -20.0% in May 14, 2025.

Crescent Biopharma, Inc. has 37.14 million shares outstanding. The public float is 26.63 million shares, elevated short interest at 16.01% of float. This equals 3.47 million shares. The short ratio is 8.89 days. Institutional investors hold 77.99% of the float. Insiders own 0.44%. Fairmount Funds Management LLC holds 2.29 million shares, BVF PARTNERS L P/IL has 1.52 million shares and Flynn James E has 1.11 million shares. Over the past six months, insider transactions show net selling. They sold 84.88 thousand shares across 16 transactions.

Crescent Biopharma, Inc. (NASDAQ:CBIO) closed at $15.96 USD, losing -$0.93 (-5.51%) from the previous close of $16.89. The stock is currently mid-range between its 52-week high and low $8.72 and $27.41. With a market capitalization of about $592.78 million, Crescent Biopharma, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.23). Key stats such as the average daily volume over the past year has been around 403.22 thousand shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Crescent Biopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joshua T. Brumm, the company employs approximately 44 people and listed since January 10, 2014. Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies.

Crescent Biopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $19.84. This means the shares are trading below this model’s fair value.

Crescent Biopharma, Inc. (NASDAQ:CBIO) shares are up 17.88% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Crescent Biopharma, Inc. trading at a premium to the broader market with a P/E of -2.23. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $25.55, suggesting 51.27% upside. Our AI forecast model points to short-term strength (7.58% over two weeks), a medium-term rise (15.51% over three months), and a longer-term gain (15.28% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Crescent Biopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.58%, with price expected at $18.17 by October 02, 2026, within a range of $17.03 to $19.27 3-Month Outlook: Projected rise of 15.51%, reaching $19.51 by December 17, 2026, with a range of $19.05 to $19.93. 1-Year Outlook: Projected gain of 15.28%, with price at $19.47 by September 17, 2027, within a range of $18.43 to $20.46.

Crescent Biopharma, Inc. trades at a P/E ratio of -2.23, slightly below the S&P 500 average, with a price-to-sales ratio of 52.79 and a price-to-book ratio of 3.16 trading at moderately above to book value. The P/FCF stands at -4.08, also below market averages.